Are amphiphysin, CV2/CRMP5, and Yo antibodies high-risk paraneoplastic neurologic antibodies?

This claim is well supported. Amphiphysin, CV2/CRMP5, and Yo/PCA-1 are high-risk paraneoplastic neurologic antibodies, meaning that a confirmed result in an appropriate neurologic syndrome strongly signals an underlying malignancy and a tumor-associated immune process.

Clinical significance

• Under the 2021 PNS-Care criteria, high-risk antibodies have cancer associations exceeding 70%. Reported frequencies are approximately 80% for amphiphysin, >80% for CV2/CRMP5, and >90% for Yo/PCA-1.
• Associated cancer patterns are clinically useful: amphiphysin is linked mainly to breast cancer and small-cell lung cancer (SCLC); CV2/CRMP5 to SCLC and thymoma; and Yo/PCA-1 to breast, ovarian, and other gynecologic cancers.
• The neurologic phenotype helps interpret a positive test: Yo is strongly linked to paraneoplastic cerebellar degeneration; CV2/CRMP5 may present with neuropathy, ataxia, optic neuritis/retinitis, or encephalomyelitis; amphiphysin often accompanies stiff-person-spectrum disease or encephalomyelitis.

Mechanistic interpretation

• These antibodies recognize intracellular neuronal antigens also expressed by tumors: amphiphysin, CRMP5, and CDR2/CDR2L, respectively.
• Tumor expression can initiate antigen presentation and a coordinated immune response involving B cells and antigen-specific, MHC-I-restricted CD8+ cytotoxic T cells. Infiltrating T cells, including perforin/granzyme-mediated injury, are considered the principal drivers of neuronal loss.
• Thus, these antibodies are chiefly biomarkers of tumor-triggered immune recognition of shared neural antigens, rather than proof of direct antibody-mediated neuronal damage.

Testing implications

• Interpretation requires a compatible syndrome and malignancy assessment. Commercial line-blot results, especially for amphiphysin and Yo, warrant orthogonal confirmation with antigen-specific and tissue-based testing, ideally in both serum and CSF.

Bottom line

• Amphiphysin, CV2/CRMP5, and Yo are confirmed high-risk paraneoplastic antibodies and credible markers of a tumor-initiated, predominantly T-cell-mediated immune attack on the nervous system.